ArticleAntimicrobial agents and chemotherapy2023
The role of rifampicin within the treatment of
Article in Antimicrobial agents and chemotherapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 26 citations in OpenAlex.
- Treatment Outcomes ofOpen forum infectious diseases · 2025Trial
- Effect of Individual Agents on Time to Culture Conversion inOpen forum infectious diseases · 2025Trial
- Falling short: Inadequate target attainment in guideline-based therapy of nontuberculous mycobacterial disease.medRxiv : the preprint server for health sciences · 2026Article
- Cytochrome P450-Mediated Metabolism of AntimycobacterialACS infectious diseases · 2026Article
- Synergistic activity of dual β-lactams againstMicrobiology spectrum · 2026Article
- Efficacies of Sequenced Monotherapies of Mycobacterium avium Lung Infection in Mouse.The Journal of infectious diseases · 2026Article
- Evaluation of clofazimine-bedaquiline combination as a candidate regimen for macrolide-resistantAntimicrobial agents and chemotherapy · 2026Article
- Clinical characteristics, antimicrobial susceptibility patterns, and treatment outcomes of nontuberculous mycobacterial diseases in eastern China: a retrospective cohort study (2019-2022).Microbiology spectrum · 2026Article
- Efficacy of drug regimens containing omadacycline in a murine model ofFrontiers in microbiology · 2026Article
- Amikacin Liposomal Inhalation Suspension: Advances in Application Against RefractoryInfection and drug resistance · 2026Review
- Article
- Association of Antimicrobial Susceptibility with Treatment Response inPathogens (Basel, Switzerland) · 2025Article
- Efficacies of sequenced monotherapies ofbioRxiv : the preprint server for biology · 2025Article
- Current and emerging treatment strategies forEwha medical journal · 2025Review
- The effects of cyclic peptide [R4W4] in combination with first-line therapy on the survival ofFrontiers in cellular and infection microbiology · 2025Article
- Non-Tuberculous Mycobacteria: Single Center Analyses of Risk Factors, Management and Mortality Outcomes of Adults with HIV.Diagnostics (Basel, Switzerland) · 2024Article
- Oral β-Lactam Pairs for the Treatment of Mycobacterium avium Complex Pulmonary Disease.The Journal of infectious diseases · 2024Article
- Low azithromycin maximal concentrations in patients concomitantly taking rifampicin: time to move away from rifampicin in the treatment of non-tuberculous mycobacteria?Antimicrobial agents and chemotherapy · 2024Article
- Growing from common ground: nontuberculous mycobacteria and bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Rifampicin is recommended for the treatment of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.